Clinical applications of anticancer drugs targeted to topoisomerase II

被引：220

作者：

Hande, KR

机构：

[1] Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Nashville, TN 37232 USA

[2] Nashville VA Med Ctr, Dept Med Oncol, Nashville, TN USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1998年 / 1400卷 / 1-3期

关键词：

topoisomerase II; cancer; drug; chemotherapy; anthracyclines; epipodophyllotoxins;

D O I：

10.1016/S0167-4781(98)00134-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed. 0167-4781/98/$ - see front matter (C) 1998 Elsevier Science B.V. All rights reserved.

引用

页码：173 / 184

页数：12

共 65 条

[1] [Anonymous], CANC CHEMOTHERAPY BI
[2] BONE-MARROW TRANSPLANTATION
ARMITAGE, JO
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) : 827 - 838
[3] BACHUR NR, 1992, MOL PHARMACOL, V41, P993
[4] INCREASED TENIPOSIDE CLEARANCE WITH CONCOMITANT ANTICONVULSANT THERAPY
BAKER, DK
RELLING, MV
PUI, CH
CHRISTENSEN, ML
EVANS, WE
RODMAN, JH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) : 311 - 315
[5] Beck W T, 1994, Adv Pharmacol, V29B, P145
[6] Belani C. P., 1994, CANCER CHEMOTH PHARM, V34, P118
[7] BENJAMIN RS, 1995, SEMIN ONCOL, V22, P11
[8] Berman E, 1993, Oncology (Williston Park), V7, P91
[9] BLUME KG, 1994, BONE MARROW TRANSPL, V14, P9
[10] DRUGS 10 YEARS LATER - EPIRUBICIN
BONADONNA, G
GIANNI, L
SANTORO, A
BONFANTE, V
BIDOLI, P
CASALI, P
DEMICHELI, R
VALAGUSSA, P
[J]. ANNALS OF ONCOLOGY, 1993, 4 (05) : 359 - 369

← 1 2 3 4 5 6 7 →